ApoPharma's Preemptive Safety Strategy For Ferriprox Includes Centralized Pharmacy Distribution
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC will consider Ferriprox (deferiprone) as second-line treatment for transfusional iron overload; the company hopes for an endorsement of its patient and provider registries as well.